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Abstract
Background: The control of soil-transmitted helminth (STH) infections currently relies on the large-scale administration of
single-dose oral albendazole or mebendazole. However, these treatment regimens have limited efficacy against hookworm
and Trichuris trichiura in terms of cure rates (CR), whereas fecal egg reduction rates (ERR) are generally high for all common
STH species. We compared the efficacy of single-dose versus triple-dose treatment against hookworm and other STHs in a
community-based randomized controlled trial in the People’s Republic of China.
Methodology/Principal findings: The hookworm CR and fecal ERR were assessed in 314 individuals aged $5 years who
submitted two stool samples before and 3–4 weeks after administration of single-dose oral albendazole (400 mg) or
mebendazole (500 mg) or triple-dose albendazole (36400 mg over 3 consecutive days) or mebendazole (36500 mg over 3
consecutive days). Efficacy against T. trichiura, Ascaris lumbricoides, and Taenia spp. was also assessed. Albendazole cured
significantly more hookworm infections than mebendazole in both treatment regimens (single dose: respective CRs 69%
(95% confidence interval [CI]: 55–81%) and 29% (95% CI: 20–45%); triple dose: respective CRs 92% (95% CI: 81–98%) and
54% (95% CI: 46–71%)). ERRs followed the same pattern (single dose: 97% versus 84%; triple dose: 99.7% versus 96%). Triple-
dose regimens outperformed single doses against T. trichiura; three doses of mebendazole – the most efficacious treatment
tested – cured 71% (95% CI: 57–82%). Both single and triple doses of either drug were highly efficacious against A.
lumbricoides (CR: 93–97%; ERR: all .99.9%). Triple dose regimens cured all Taenia spp. infections, whereas single dose
applications cured only half of them.
Conclusions/Significance: Single-dose oral albendazole is more efficacious against hookworm than mebendazole. To
achieve high CRs against both hookworm and T. trichiura, triple-dose regimens are warranted.
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Introduction
Hundreds of millions of people are infected with the common
soil-transmitted helminths (STHs), namely hookworms (Ancylostoma
duodenale and Necator americanus), Ascaris lumbricoides and Trichuris
trichiura, many by multiple species concurrently [1–5]. Taenia spp.
infections are also widespread [6,7]. STHs and taeniasis/
cysticercosis belong to the neglected tropical diseases (NTDs)
and are responsible for mainly chronic and often inconspicuous
morbidity [8,9]. Iron-deficiency anemia, malnutrition, and
impaired physical and cognitive development have all been
attributed to STH infections [1,5,10]. Taenia solium cysticercosis
is a major cause of epilepsy and other neurological disorders in
developing countries [11,12].
The current strategy for STH control in highly endemic areas
focuses on morbidity control through large-scale administration of
single-dose anthelminthics to at-risk populations, particularly
school-aged children [9,13,14]. Due to the zoonotic nature of
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sector [6,15–17]. At present, only four drugs are recommended by
the World Health Organization (WHO) for treating STH
infections [13,18]. The global STH control relies on two of them
– albendazole and mebendazole – both benzimidazole carba-
mates. Albendazole [19] and mebendazole [20] display a broad
spectrum of activity and are administered orally, usually at a single
dose of 400 mg and 500 mg, respectively [13,18,21]. Children
below the age of 1 year and pregnant women in the first trimester
of pregnancy are not eligible for treatment [13].
Albendazole and mebendazole have been extensively used
worldwide for more than 30 years, both as stand-alone treatments
and, more recently, in combination with other drugs, e.g.,
praziquantel (against schistosomiasis and food-borne trematodia-
sis) or ivermectin (against lymphatic filariasis) [9,22–24]. Surpris-
ingly though, only few clinical trials compared the efficacy of
albendazole and mebendazole against STHs. Rather, availability,
cost, drug donation programs, and policy instead of the local
parasite spectra and evidence determine the choice of which
anthelminthic drug is deployed. Justification for the indiscriminate
use of either drug is derived from high egg reduction rates (ERRs)
achieved with both albendazole and mebendazole, and the
assumption that morbidity is a function of infection intensity
[25,26]. However, a recent meta-analysis of randomized placebo-
controlled single-dose drug efficacy trials pointed to a marked
superiority of albendazole over mebendazole against hookworm,
high efficacy (in terms of cure rate [CR]) of both drugs against A.
lumbricoides, and disappointing efficacy of either drug against T.
trichiura [18]. Few data are available regarding ERRs.
The aim of this randomized controlled trial was to assess the
efficacy of standard single-dose versus triple-dose oral albendazole
and mebendazole against hookworm and other STH infections in
a highly endemic but virtually benzimidazole-naı ¨ve population in
the People’s Republic of China (P.R. China).
Methods
The protocol for this trial and the supporting CONSORT
checklist are available as supporting information; see Protocol S1
and Checklist S1.
Study Area, Study Period, and Participants
The study was conducted between October and December
2008 in Nongyang, a village located in Menghai county, Yunnan
province, P.R. China. Details of the study area, population and
epidemiological characteristics, including the prevalence of STHs,
Taenia spp., and intestinal protozoa, have been described before
[3,27,28]. The local prevalence of each A. lumbricoides, hookworm,
and T. trichiura exceeded 85% in a survey conducted in 2006 [3].
Upon completion of the 2006 survey, compound mebendazole
(mebendazole 100 mg/tablet+levamisole hydrochloride 25 mg/
tablet, 2 tablets per day for 3 consecutive days) was distributed to
the village population. No further interventions took place until
the present study.
Ethics
The study was approved by the Ethics Committee of Basel
(no. 294/08) and the Academic Board of the National Institute of
Parasitic Diseases, Chinese Center for Disease Control and
Prevention in Shanghai (no. 2008091701). The trial was registered
with Current Controlled Trials (identifier: ISRCTN47375023).
The study objectives and procedures were discussed with the
village head, village committee, and local health care officials who
informed the residents. Individuals who were interested to
participate signed an informed consent form in Chinese (parents
or legal guardians in case of minors aged 5–17 years). Upon study
completion, albendazole was provided for treatment of study
participants found to be infected at evaluation, drop-outs, sick
individuals upon recovery, and pregnant women once beyond the
first trimester.
Interventions, Trial Medication, and Outcome Measures
The trial was designed as a community-based open-label,
outcome assessors-blinded randomized controlled trial with four
arms: (i) single-dose albendazole (400 mg), (ii) single-dose meben-
dazole (500 mg), (iii) triple-dose albendazole (36400 mg, given
over 3 consecutive days), and (iv) triple-dose mebendazole
(36500 mg, given over 3 consecutive days). No placebo drugs
were given to individuals assigned to single dose treatment (open
label).
Albendazole (ZentelH; lot no 08060407) was commercially
obtained from Sino-American Tianjin SmithKline and French
Laboratories Ltd., a Chinese joint venture of GlaxoSmithKline
Plc. Mebendazole (VermoxH; lot nos. 8CL4F00 and 7CL8900),
produced by Johnson & Johnson/Janssen-Cilag S.p.A., was
provided by the WHO regional office in Hanoi, Vietnam.
The primary outcome considered was CR against hookworm 3–
4 weeks following dosing. Changes in hookworm infection
intensity, as determined by ERR, and efficacy against A.
lumbricoides and T. trichiura served as secondary outcomes.
Additionally, the effects of all four treatment regimens on Taenia
spp. were assessed.
Eligibility Criteria and Sample Size
Eligible for inclusion were all residents of Nongyang aged 5
years and above. The following exclusion criteria were applied:
presence of diagnosed or perceived chronic disease or other
conditions likely to interfere with anthelminthic treatment (e.g.,
hypersensitivity to anthelminthics), pregnancy (verbally assessed at
enrolment and again before treatment), recent history of
anthelminthic treatment, and participation in other trials (within
1 month).
The intended sample size at enrolment was 370 individuals,
based on the following assumptions: a total of 176 individuals (44
in each of the four treatment arms) would be needed to detect
differences in the CR following different treatments for the cure of
hookworm infections with 80% power using a 2-sided statistical
test with an a-level of 0.05 and CRs of albendazole and
mebendazole against hookworm infections of 75% and 45%.
According to Keiser and Utzinger [18], the respective CRs are
78% and 23%; the higher estimate for the CR of mebendazole was
employed in order to include a safety margin. The local prevalence
of hookworm infections was assumed to be 60% and compliance
was estimated to be 80%. Recruitment was to be stopped once 400
individuals had been enrolled.
Field and Laboratory Procedures
Families were contacted in batches of 20–30 (,80–120
potential participants) based on family registry numbers. Interested
family members were invited to the local primary school for
further information and enrolment. No monetary compensation
was offered for participation. Participants answered a short
questionnaire investigating demographic and health-related issues,
and were given a stool collection container labeled with a unique
identifier and their full name. The ability of all study participants
to recognize their collection container was determined, and the
importance of using the own receptacle emphasized. Each
morning, filled containers were collected, and a new container
Efficacy of Anthelmintic Drugs
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participant.
Stool samples were forwarded to a nearby laboratory and
processed on the collection day. First, samples were visually
inspected for adult A. lumbricoides and Taenia spp. proglottids.
Second, two 41.7 mg Kato-Katz thick smears [29] were prepared
from each sample. Depending on the ambient temperature and
considering over-clearance of hookworm eggs, slides were read
within 30–90 min of preparation [30]. At least 5% of the daily
diagnoses were cross-checked by the principal investigator.
Procedures for the evaluation of the treatment efficacy com-
menced 3 weeks post-treatment, lasted 2 weeks, and involved all
participants given at least one drug dose. The same approach was
adhered to as during the baseline survey.
Randomization
All participants who had submitted at least one stool sample
during the baseline survey were randomly assigned either to the
albendazole or the mebendazole arm of the study. In an
independent randomization step, single or triple dose treatment
using two computer-generated random sequences of 0 and 1
which were aligned with the list of participants in ascending order
of their identification numbers. The eligible individuals were
neither stratified by age nor sex before randomization.
Drug Administration
For each day of treatment, an envelope of the type locally used
to hand out drugs was labeled with the name, identification
number, and number of treatment, loaded with the appropriate
drugs, and sealed. The distribution teams directly observed drug
intake after asking about acute health problems and pregnancy
status. Study participants had been reminded not to drink alcohol
on treatment days and to report emerging health problems to the
study physician (a medical doctor from a nearby hospital who
visited the village each morning after drug distribution), any
member of the research team, or the head of the village. On the
second morning – 36 hours after the first dosing – all participating
households were visited and participants actively solicited to report
any potential adverse events. Reported health problems were
classified by the study physician and graded by severity according
to a pre-defined scale.
Statistical Analysis
Data were double-entered in EpiData version 3.1 (EpiData
Association; Odense, Denmark) or MicrosoftH Excel 2002
(Microsoft; Redmond, USA). After removing discrepancies, the
datasets were aligned, and the accuracy of the merged database
verified against the original data through random cross-checking.
All analyses were performed on a per-protocol basis. Only
participants with complete datasets were included.
Baseline and post-treatment prevalences were estimated, and
CRs determined for each study arm. The extent of prevalence
reductions and differences in CRs between groups were explored,
using a 2-sided 2-sample test of proportions, which tests the
equality of proportions using large-sample statistics. For each
participant, the species-specific helminth infection intensity at
baseline and at treatment evaluation was calculated and expressed
as eggs per gram of stool (EPG), based on the arithmetic mean of
the quadruplicate Kato-Katz thick smear readings, multiplied by a
factor 24. Arithmetic and geometric means and ERRs were
calculated according to Montresor et al. [31]. Confidence limits
for the ERR were calculated using a bootstrap re-sampling
method with 2000 iterations. Significant treatment group
differences were defined by non-overlapping 95% confidence
limits. For all tests, a p-value of 0.05 was considered the limit of
statistical significance, and 95% confidence intervals (CIs) were
calculated as appropriate. Statistical analyses were done in
STATA version 10.1 (StataCorp LP; College Station, USA),
bootstrap confidence intervals were calculated using R 2.9.1.
Results
Participant Flow and Baseline Characteristics
As detailed in Figure 1, at least one stool sample was available
from 378 people who were randomly assigned to one of the four
treatment arms. Among them, 314 (83%) could be included in the
final analysis. The composition of all four groups with regard to
sex and age was comparable and baseline prevalences of A.
lumbricoides, T. trichiura, hookworm and Taenia spp. were 90%,
75%, 73% and 11%, respectively, with no differences among the
four treatment arms (Table 1).
Efficacy Against Hookworm and Other STHs
A single dose of albendazole cured 69% (95% CI: 55–81%) of
the hookworm infections, while single-dose mebendazole only
cured 31% (95% CI: 20–45%), significantly less (Table 2 and
table 3). Triple doses of either drug were significantly more
efficacious than single-dose regimens, but the difference between
the two drugs persisted: triple-dose albendazole cured significantly
more hookworm infections (92%, 95% CI: 81–98%) than triple-
dose mebendazole (58%, 95% CI: 46–71%).
Triple-dose mebendazole exhibited the highest reduction in T.
trichiura prevalence (CR: 71%), followed by triple-dose albendazole
(56%). Single dose applications were found to be significantly less
efficacious (mebendazole: 40%, albendazole: 34%). In both cases,
the differences between drug-specific CRs were not statistically
significant. As expected, both albendazole and mebendazole
cleared most of the A. lumbricoides infections with observed CRs
ranging between 93% and 97%. The efficacies of albendazole and
mebendazole were comparable. Triple-dose treatment tended to
be slightly more efficacious than single-dose treatment, but the
difference was not statistically significant. For Taenia spp., a single
dose of either drug cured about one half of the infections; triple-
dose administration cured all infections.
Table 4 and 5 (and in greater detail the Figure S1) show the
baseline EPGs and changes following treatment. In general, the
efficacy regarding ERRs followed a similar pattern as that of CRs.
Albendazole outperformed mebendazole in terms of hookworm
ERR, whereas mebendazole tended to be more efficacious against
T. trichiura. Triple-dose regimens exhibited significantly higher
ERRs against both parasites. All treatments resulted in
ERRs.99.9% against A. lumbricoides. The median hookworm
egg count in the 228 infected participants was 84 EPG at baseline
and 30 EPG in those 92 still infected after treatment. The
administration of three doses of albendazole resulted in the highest
ERR against hookworm (99.7%; 95% CI: 99–99.9%). Single-dose
albendazole with an ERR of 97% (95% CI: 95–99%) performed
as well as triple-dose mebendazole (96%, 95% CI: 93–98%). A
single dose of mebendazole resulted in an ERR of only 84% (95%
CI: 73–90%). For T. trichiura, the administration of triple doses
resulted in an ERR of 97% for mebendazole, and 94% for
albendazole. With ERRs of 83% and 77%, respectively, single
doses performed significantly worse.
Adverse Events
Thirteen study participants (4.1%) reported between one and
five adverse events following drug administration, mostly in the
morning of the third drug distribution day (about 12 hours after
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questioning. Four of these individuals were treated with a single
dose (3 with mebendazole, 1 with albendazole) while the remaining
nine were treated with triple mebendazole (n=5) or triple
albendazole (n=4). One symptom was reported by nine individuals,
two symptoms by two individuals (1 treated with triple albendazole,
1 with triple mebendazole), threesymptomsby one individual(triple
mebendazole) and five symptoms by one individual (triple
mebendazole). Adverse events included headache (n=3; all
mebendazole), abdominal cramps (n=3; 2 mebendazole, 1
albendazole) and the closely related ‘‘full stomach’’ (n=2;
mebendazole), and waist pain (n=1; albendazole). Two individuals
each reported vomiting, including production of A. lumbricoides
worms (1 albendazole, 1 mebendazole), diarrhea (2 mebendazole),
fatigue (1 albendazole, 1 mebendazole), and chills (2 mebendazole).
Vertigo (albendazole), throat pain (albendazole), fever (mebenda-
zole), and a swollen face (mebendazole) were each reported once.
None of the study participants requested medical interventions as
adverse events were mild and self-limiting. More women than men
reported adverse events (ten women among whom four treated with
albendazole and six treated with mebendazole versus three men;
P=0.046) but there was no significant association between the
report of adverse events and age, drug, or number of treatments
according to the Fisher’s exact test.
Figure 1. Participation and drop-out at various stages in a trial assessing the efficacy of anthelminthic drugs. Participation and causes
for drop-out at various stages in a randomized controlled trial assessing the efficacy of single-dose versus triple-dose albendazole and mebendazole
against STH infections and Taenia spp. in a Bulang ethnic minority community in Yunnan province, P.R. China in late 2008.
doi:10.1371/journal.pone.0025003.g001
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This randomized controlled trial comparing the efficacy of
single and triple dose albendazole and mebendazole confirmed
that single oral albendazole is more efficacious than mebendazole
against hookworm infections [18,32]. It also corroborated that
triple-dose regimens result in significantly higher CRs than
recommended and widely used single-dose regimens [13,33]. A
single dose of mebendazole only cured 31% of the hookworm
infections, while the highest CR, after triple albendazole, was
92%. Even triple administration of mebendazole was less
efficacious than a single dose of albendazole. Keiser and Utzinger’s
meta-analysis [18] estimated a CR of only 15% after single-dose
mebendazole, and a value comparable to that found in the present
study after single-dose albendazole (present study: 69%, meta-
analysis: 72%). With regard to ERRs, all four drug regimens
resulted in significant reductions among those infected at baseline.
A triple dose of mebendazole was significantly more efficacious
than a single dose.
The number of T. trichiura infections in each treatment arm was
significantly, though only moderately reduced, in line with
previous findings [18,33,34]. As expected, triple doses resulted in
higher CRs than a single dose regardless of the drug. Worryingly,
the highest CR observed was only 71% following triple-dose
mebendazole. Single and triple doses of mebendazole resulted in
higher ERRs than the respective number of albendazole
administrations. With regard to A. lumbricoides infections, high
CRs were observed for both drugs even at a single dose;
Table 1. Demographic characteristics of the participants in a trial assessing the efficacy of anthelminthic drugs.
Total
Single-dose
albendazole
Single-dose
mebendazole
Triple-dose
albendazole
Triple-dose
mebendazole
Total n (%) 314 (100) 82 (100) 81 (100) 68 (100) 83 (100)
Sex: Female n (%) 151 (48.1) 35 (42.7) 39 (48.2) 36 (52.9) 41 (49.4)
Age n (%)
- 5–14 years 42 (13.4) 9 (11.0) 8 (9.9) 14 (20.6) 11 (13.3)
- 15–24 years 88 (28.0) 26 (31.7) 20 (24.7) 19 (27.9) 23 (27.7)
-2 5 + years 184 (58.6) 47 (57.3) 53 (65.4) 35 (51.5) 49 (59.0)
Parasite n (%)
- Hookworm (95% CI) 228 (72.6; 67.7–77.5) 55 (67.1) 58 (71.6) 50 (73.5) 65 (78.3)
- Ascaris lumbricoides (95% CI) 284 (90.4; 87.2–93.7) 78 (95.1) 71 (87.7) 63 (92.6) 72 (86.7)
- Trichuris trichiura (95% CI) 234 (74.5; 69.7–79.3) 65 (79.3) 63 (77.8) 48 (70.6) 58 (69.9)
- Taenia spp. (95% CI) 33 (10.5; 7.1–13.9) 10 (12.2) 6 (7.4) 7 (10.3) 10 (12.0)
Demographic characteristics and baseline helminth prevalence of the study participants in a randomized controlled trial assessing the efficacy of single-dose and triple-
dose albendazole versus mebendazole against STH infections and Taenia spp. in a Bulang ethnic minority community in Yunnan province, P.R. China, stratified by
treatment arm.
doi:10.1371/journal.pone.0025003.t001
Table 2. Prevalences and cure rates in a trial assessing the efficacy of anthelminthic drugs (hookworm and Ascaris lumbricoides).
Single-dose
albendazole (n=82)
Single-dose
mebendazole (n=81)
Triple-dose
albendazole (n=68)
Triple-dose
mebendazole (n=83)
Hookworm
Prevalence at baseline [% (n)] 67.1 (55) 71.6 (58) 73.5 (50) 78.3 (65)
Prevalence after treatment [% (n)] 20.7 (17) 50.6 (41) 5.9 (4) 36.1 (30)
New positives at evaluation 0103
Cure rate [% (95% CI)]
excluding new positives at evaluation 69.1 (55.2–80.9) 31.0 (19.5–44.5) 92.0 (80.8–97.8) 58.5 (45.6–70.6)
Difference between drug-specific cure rates [% (95% CI)] 38.1 (21.0–55.1)*** Reference 33.5 (19.4–47.7)*** Reference
Difference single- vs. triple-dose cure rates [% (95% CI)] Reference Reference 22.9 (8.6–37.2)** 27.4 (10.5–44.3)**
Ascaris lumbricoides
Prevalence at baseline [% (n)] 95.1 (78) 87.7 (71) 92.6 (63) 86.7 (72)
Prevalence after treatment [% (n)] 3.7 (3) 6.2 (5) 2.9 (2) 6.0 (5)
New positives at evaluation 0000
Cure rate [% (95% CI)]
excluding new positives at evaluation 96.1 (89.1–99.2) 93.0 (84.3–97.7) 96.8 (89.0–99.6) 93.1 (84.5–97.7)
Difference between drug-specific cure rates [% (95% CI)] 3.2(24.1–10.5) Reference 3.8 (23.5–11.1) Reference
Difference single- vs. triple-dose cure rates [% (95% CI)] Reference Reference 0.7 (25.4–6.8) 0.1 (28.2–8.4)
Cure rates following single-dose and triple-dose albendazole versus mebendazole against STH infections and Taenia spp., and comparisons between treatment arms.
* P value,0.05, ** P value,0.01, *** P value,0.001.
doi:10.1371/journal.pone.0025003.t002
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analysis [18,33].
Attention was paid to enhance the sensitivity of STH diagnosis
by examining multiple Kato-Katz thick smears before and after
drug administration [3,35,36]. The low number of ‘‘new’’
infections found at treatment evaluation (Table 2 and table 3)
indicates that a high sensitivity had been achieved despite the
rather low density of hookworm and T. trichiura eggs. Because of
the low Taenia spp. prevalence and since the study was not
designed to evaluate treatment efficacy against this parasite, the
respective results should be interpreted with caution. The
conventional indicator for the successful cure of Taenia spp.
infections – i.e., recovery of the scolex – is no definitive proof
whenever individuals harbor several worms, and is difficult to
perform outside an institutional setting. We focused on the
presence of proglottids and eggs.
An open-label trial design was adhered to due to the
complexities and high cost for implementing a double-blind trial
in a field setting. We are confident that this did not negatively
impact on the validity of the results since outcome assessors were
blinded. One individual assigned to the triple albendazole group
switched to the single-dose group, and in two instances the drug
assignment was changed between members of the same family due
to an initial mix-up. We used logistic regression to assess if our
results were sensitive to the potential effect modifiers age and sex.
Age was treated as a categorical variable (categories as in Table 1)
Table 3. Prevalences and cure rates in a trial assessing the efficacy of anthelminthic drugs (Trichuris trichiura and Taenia spp.).
Single-dose
albendazole (n=82)
Single-dose
mebendazole (n=81)
Triple-dose
albendazole (n=68)
Triple-dose
mebendazole (n=83)
Trichuris trichiura
Prevalence at baseline [% (n)] 79.3 (65) 77.8 (63) 70.6 (48) 69.9 (58)
Prevalence after treatment [% (n)] 53.7 (44) 49.4 (40) 32.4 (22) 25.3 (21)
New positives at evaluation 1214
Cure rate [% (95% CI)]
excluding new positives at evaluation 33.8 (22.6–46.6) 39.7 (27.6–52.8) 56.2 (41.2–70.5) 70.7 (57.3–81.9)
Difference between drug-specific cure rates [% (95% CI)] 25.8 (222.5–10.8) Reference 214.4 (232.7–3.8) Reference
Difference single- vs. triple-dose cure rates [% (95% CI)] Reference Reference 22.4 (4.3–40.5)* 31.0 (14.2–47.8)***
Taenia spp.
Prevalence at baseline [% (n)] 12.2 (10) 7.4 (6) 10.3 (7) 12.0 (10)
Prevalence after treatment [% (n)] 7.3 (6) 4.9 (4) 0 (0) 1.2 (1)
New positives at evaluation 1101
Cure rate [% (95% CI)]
excluding new positives at evaluation 50.0 (18.7–81.2) 50.0 (11.8–88.2) 100 (59.0–100) 100 (69.2–100)
Difference between drug-specific cure rates [% (95% CI)] 0 (NA) Reference 0 (NA) Reference
Difference single- vs. triple-dose cure rates [% (95% CI)] Reference Reference 50.0 (19.0–80.1)* 50.0 (10.0–90.0)*
Cure rates following single-dose and triple-dose albendazole versus mebendazole against STH infections and Taenia spp., and comparisons between treatment arms.
* P value,0.05, ** P value,0.01, *** P value,0.001.
doi:10.1371/journal.pone.0025003.t003
Table 4. Infection intensity and egg reduction rates in a trial assessing the efficacy of anthelminthic drugs (geometric mean).
Single-dose
albendazole
Single-dose
mebendazole
Triple-dose
albendazole
Triple-dose
mebendazole
Hookworm [n] 55 58 50 65
EPG at baseline (geometric mean) 69 73 90 86
EPG after treatment (geometric mean) 2 12 0.3 3
ERR; difference in geometric mean [%; (95% CI)] 97.3 (95.2–98.7)
b 83.6 (72.9–90.3)
a 99.7 (99.1–99.9)
c 96.4 (93.3–98.2)
b
Ascaris lumbricoides [n] 78 71 63 72
EPG at baseline (geometric mean) 8,442 7,855 6,485 8,435
EPG after treatment (geometric mean) 0.1 0.5 0.2 0.2
ERR; difference in geometric mean [%; (95% CI)] .99.9 (.99.9–100)
a .99.9 (.99.9–.99.9)
a .99.9 (.99.9–100)
a .99.9 (.99.9–.99.9)
a
Trichuris trichiura [n] 65 63 48 58
EPG at baseline (geometric mean) 58 47 68 55
EPG after treatment (geometric mean) 14 8 4 1
ERR; difference in geometric mean [%; (95% CI)] 76.7 (62.6–86.1)
a 82.5 (71.0–89.6)
a,b 94.0 (89.4–96.8)
b,c 97.3 (94.9–98.8)
c
Infection intensities among those infected at baseline expressed as EPG and ERR following single-dose and triple-dose albendazole versus mebendazole against STH
infections, and comparisons between treatment arms. Different letters (a, b, c) designate significant differences of ERR between treatment arms, defined by non-
overlapping 95% confidence limits (calculated by bootstrap resampling).
doi:10.1371/journal.pone.0025003.t004
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showed noteworthy differences between the crude and adjusted
models with respect to the point estimates or CIs of the odds ratios.
The sole exception was the treatment regimen (single dose versus
triple dose) for which adjustment for sex and age showed stronger
effects for both drugs in the case of T. trichiura.
The susceptibility of the two human hookworm species to
albendazole is known to be unequal, with CRs for the more
pathogenic A. duodenale higher than that for N. americanus [37]. Both
hookworm species are endemic in P.R. China but the locally
predominant species probably is N. americanus according to a
polymerase chain reaction (PCR)-based [38] species identification
performed in a neighboring area [39]. Multiple-species intestinal
helminth infections are common [4] but no associations between
species have been found and the high prevalence of multi-
parasitism in the study population is unlikely to diminish the
validity of the findings for other settings.
Two additional observations are worth discussing. First, the A.
lumbricoides CR did not differ significantly (p.0.05) between
infection-intensity classes as defined by WHO [40]. Second, the
baseline prevalence of A. lumbricoides and hookworm was higher
among females than males. At evaluation, the difference persisted
for hookworm, but had disappeared for A. lumbricoides, probably
owing to the high CR against the latter parasite. In the case of T.
trichiura, comparable prevalences were found for males and females
at baseline, but treatment with either drug reduced the prevalence
in males more markedly than in females.
The raw data of our randomized controlled trial is provided as
supplementary files (Data S1 and Codes S1). In the spirit of trial
registration prior to conducting clinical research, of open-access
publishing, and of evidence-based medicine, we believe that others
might find our data useful (e.g. for subsequent meta-analysis of
drugs used against STHs). We hope that other clinical investiga-
tors and research groups will follow our example.
In conclusion, single-dose albendazole and mebendazole are
highly efficacious against A. lumbricoides, albendazole is superior to
mebendazole for treating hookworm, and mebendazole slightly
outperforms albendazole with regard to treating T. trichiura.T o
achieve high CRs against hookworm and T. trichiura infections,
triple dose regimens should be considered. Yet, for T. trichiura,
even triple doses only resulted in the cure of a bit more than half of
the infections, a result corroborating previous reports [33,41].
Triple-dose treatment is commonly deemed unfeasible in the
context of large-scale drug administration programs based on
logistical and organizational considerations [42], an issue which
needs careful attention. To justify rolling out triple dose treatment,
the additional efforts and costs required to do so must be weighed
against the benefit, i.e., the higher treatment efficacy, and hence
the prevention of harm. From a patient perspective, triple dose
treatment appeared acceptable in the present study. Our findings
therefore underscore the need for discovery and development of
novel drugs for the management of trichuriasis [21,33]. Until new
drugs become available, it is recommended to investigate ways to
boost the efficacy of existing anthelminthics, including combina-
tion therapy (e.g., albendazole or mebendazole plus ivermectin)
[21,33,34] and multiple dosing [21,33]. The higher efficacy of
triple doses for treating Taenia spp. infections further tips the
balance in favor of triple dose schedules in certain areas. With
regard to large-scale interventions, the present results call for a
more nuanced approach than the standard single-dose mono-drug
distribution. Indeed, our findings emphasize the need for careful
assessment of the locally endemic STHs, and the adaptation of the
employed anthelminthic drug regimens to the prevailing situation.
In populations primarily parasitized by A. lumbricoides and/or
hookworm infections, single or – in case of a high prevalence or
high-intensity hookworm infections – triple-dose albendazole
might suffice. Mebendazole treatment with one or better three
doses should be adopted in areas with a high prevalence of T.
trichiura (and possibly A. lumbricoides), but a lower number of
hookworm infections. In areas where all three species are co-
endemic, alternation between albendazole and mebendazole as
well as co-administration of different anthelminthic drugs should
be considered.
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Checklist S1 CONSORT checklist.
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Figure S1 Frequency distribution of baseline EPGs and
changes following treatment.
(PNG)
Data S1 Raw data of the trial.
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Table 5. Infection intensity and egg reduction rates in a trial assessing the efficacy of anthelminthic drugs (arithmetic mean).
Single-dose
albendazole
Single-dose
mebendazole
Triple-dose
albendazole
Triple-dose
mebendazole
Hookworm [n] 55 58 50 65
EPG at baseline [median (25%–75%)] 78 (30–180) 84 (36–180) 84 (30–210) 102 (30–216)
EPG after treatment [median (25%–75%) [n]] 30 (12–43) [17] 30 (18–126) [41] 36 (18–56) [4] 18 (12–72) [30]
Ascaris lumbricoides [n] 78 71 63 72
EPG at baseline [median (25%–75%)] 9600 (3,576–24,504) 10,260 (4,476–18,744) 8736 (2,382–22,056) 7956 (4,608–19,050)
EPG after treatment [median (25%–75%) [n]] 18 (6–396) [3] 1488 (24–2,904) [5] 384 (18–750) [2] 6 (6–6) [5]
Trichuris trichiura [n] 65 63 48 58
EPG at baseline [median (25%–75%)] 66 (24–138) 48 (18–144) 78 (36–132) 51 (18–138)
EPG after treatment [median (25%–75%) [n]] 48 (18–144) [44] 39 (18–57) [40] 30 (18–78) [22] 18 (6–30) [21]
Infection intensities among those infected at time of observation expressed as EPG and ERR following single-dose and triple-dose albendazole versus mebendazole
against STH infections, and comparisons between treatment arms.
doi:10.1371/journal.pone.0025003.t005
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